R-BAC PROTOKOLÜ

Kaynaklar:

1-Visco, C., S. Finotto, R. Zambello, et al. 2013. "Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation." J Clin Oncol 31(11):1442-1449.

2-Visco, C., A. Chiappella, L. Nassi, et al. 2017. "Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi." Lancet Haematol 4(1):e15-e23.

3-Pinter, M., M. Trauner, M. Peck-Radosavljevic, et al. 2016. "Cancer and liver cirrhosis: implications on prognosis and management." ESMO Open 1(2):e000042.

4-Branca, A., I. Gianesello, L. Brugnaro, et al. 2016. "Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience" Blood 126(23):2710

5- Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511–18. 

6-Dreyling M, Kluin-Nelemans HC, Beà S, et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma 2013; 54: 699–707.

7- Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone signifi cantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–92. 

8-Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression free survival. J Clin Oncol 2002; 20: 1288–94. 

9- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as fi rst-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–10.